Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorundrostat (Primary)
  • Indications Hypertension; Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE-HTN
  • Sponsors Mineralys Therapeutics

    • Most Recent Events

    • 10 Mar 2025 Primary endpoint has been met.
    • 10 Mar 2025 Results published in the Media Release
    • 07 Mar 2025 According to a Mineralys Therapeutics media release,the company announced that it will host a conference call and webinar to announce topline results from Advance-HTN pivotal trial on Monday, March 10, 2025, at 8:00 a.m. ET.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top